联合检测血清SCC、TSGF和CEA在宫颈癌诊断与临床分期中的应用价值分析

Analysis of the value of combined test of serum SCC,TSGF and CEA in diagnosis and clinical staging of cervical cancer

目的分析联合检测鳞状细胞癌抗原(SCC)、恶性肿瘤特异生长因子(TSGF)和癌胚抗原(CEA)在宫颈癌诊断与临床分期中的应用价值。方法选取50例确诊宫颈癌患者作为宫颈癌组,另选取50例健康体检者作为健康组。检测并对比两组受试者的血清肿瘤标志物水平,以病理结果为金标准,分析血清肿瘤标志物单一检测与联合检测对病理类型的阳性检出情况以及对不同临床分期患者的检出情况。结果宫颈癌组的SCC、TSGF、CEA水平分别为(7.13±1.35)ng/ml、(81.35±15.73)U/ml、(33.12±5.62)U/ml,显著高于健康组的(0.65±0.42)ng/ml、(49.26±7.85)U/ml、(3.47±1.27)U/ml,差异有统计学意义(P<0.05)。鳞癌患者的SCC阳性检出率为69.70%(23/33),高于腺癌患者的23.53%(4/17),差异有统计学意义(χ2=9.628,P=0.002<0.05);鳞癌患者的TSGF、CEA阳性检出率分别为39.39%(13/33)、24.24%(8/33),低于腺癌患者的70.59%(12/17)、58.82%(10/17),差异有统计学意义(P<0.05);鳞癌患者的联合检测阳性率为84.85%(28/33),与腺癌患者的82.35%(14/17)比较,差异无统计学意义(P>0.05)。随着临床分期级别的升高,单一检测、联合检测的阳性率升高。Ⅰ期和Ⅱ期的联合检测阳性率为78.57%(22/28),Ⅲ期和Ⅳ期的联合检测阳性率为90.91%(20/22),Ⅰ期和Ⅱ期的联合检测阳性率与Ⅲ期和Ⅳ期比较,差异无统计学意义(P>0.05)。结论联合检测血清SCC、TSGF和CEA在宫颈癌诊断与临床分期中均具有一定应用价值。

Objective To analyze the practical value of combined test of serum squamous cell carcinoma antigen(SCC),tumor specific growth factor(TSGF)and carcinoembryonic antigen(CEA)in diagnosis and clinical staging of cervical cancer.Methods 50 patients with confirmed cervical cancer were selected as the cervical cancer group,and another 50 healthy subjects were selected as the healthy group.The serum tumor marker levels of the two groups were measured and compared,and the pathological results were used as the gold standard to analyze the positive detection of serum tumor markers by single test versus combined test for pathological types and for patients with different clinical stages.Results The levels of SCC,TSGF and CEA in the cervical cancer group were(7.13±1.35)ng/ml,(81.35±15.73)U/ml,and(33.12±5.62)U/ml,which were significantly higher than(0.65±0.42)ng/ml,(49.26±7.85)U/ml and(3.47±1.27)U/ml of the healthy group,and the difference was statistically significant(P<0.05).The positive detection rate of SCC in patients with squamous cell carcinoma was 69.70%(23/33),which was higher than 23.53%(4/17)in patients with adenocarcinoma,and the difference was statistically significant(χ2=9.628,P=0.002<0.05).The positive detection rates of TSGF and CEA in patients with squamous cell carcinoma were 39.39%(13/33)and 24.24%(8/33),which were lower than 70.59%(12/17)and 58.82%(10/17)in patients with adenocarcinoma,and the difference was statistically significant(P<0.05).The positive rate of the combined test in patients with squamous cell carcinoma was 84.85%(28/33),which was not statistically significant compared with 82.35%(14/17)in patients with adenocarcinoma(P>0.05).With the increase of clinical stage level,the positive rate of single test and combined test increased.The positive rate of the combined test of stageⅠand stageⅡwas 78.57%(22/28),and the positive rate of the combined test of stageⅢand stageⅣwas 90.91%(20/22).There was no statistically significant difference between the positive rate of the combined test for stageⅠand stageⅡcompared with stageⅢand stageⅣ(P>0.05).Conclusion The combined test of serum SCC,TSGF and CEA has certain application value in the diagnosis and clinical staging of cervical cancer.